Effective in 1994, we continuously carried out pharmacoeconomics research worldwide.

Professor Rychlik also served as an independent expert for the German parliament and for the conservative party in different legal affairs on drug policy.

We offer:

  • Health Technology Assessments (HTAs)
  • Reimbursement Dossiers
  • Value Stories and Dossiers
  • Secondary Data Analysis of sick funds
  • Modelling